---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-010371"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:04:32.954360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M

## Summary
- Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.
- Net loss from continuing ops $7.7M vs $35.4M prior year; adjusted EBITDA $22.0M (+28.1%).
- Full year 2023 revenue $512.3M (flat YoY); net loss $121.2M vs $144.7M; adj. EBITDA $88.9M (+29.5%).
- Appointed Rob Claypoole as President and CEO, effective prior to Q4 close.
- FY2024 guidance: net sales $520-535M, adjusted EBITDA $89-94M, non-GAAP EPS $0.12-$0.20.

## SEC filing metadata
- accession: 0001628280-24-010371
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/bvs-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-010371
- JSON: https://secwatch.observer/filing/0001628280-24-010371.json
- Plain text: https://secwatch.observer/filing/0001628280-24-010371.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported Fourth Quarter 2023 results: revenue $135.4 million, net income net loss of $7.7 million, EPS ($0.10) loss per share.
  - Period: Fourth Quarter 2023
  - Revenue: $135.4 million
  - Net income: net loss of $7.7 million
  - EPS: ($0.10) loss per share
  - Result: reported results
  source text: For the fourth quarter, worldwide revenue totaled $135.4 million, an increase of 7.6% compared to the prior year. On an organic* basis, revenue increased 14.3%, driven by more than 20% growth in Pain Treatments and Surgical Solutions. The Company also reported a fourth quarter net loss from continuing operations of $7.7 million, compared to net loss from continuing operations of $35.4 million in the prior-year period. Adjusted EBITDA* from continuing operations of $22.0 million advanced 28.1% from $17.2 million last year due to strong revenue growth and disciplined cost management. Loss per share of Class A common stock from continuing operations was $0.10 per share, compared to a loss of $0.40 per share last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm
- Earnings Releases
  Bioventus Inc. reported Full Year 2024 results: revenue $520 million to $535 million, EPS $0.12 to $0.20. Guidance initiated.
  - Period: Full Year 2024
  - Revenue: $520 million to $535 million
  - EPS: $0.12 to $0.20
  - Guidance: initiated
  - Result: guidance update
  source text: Bioventus introduced its financial guidance for full-year 2024. The Company expects: • Net sales of $520 million to $535 million • Adjusted EBITDA* of $89 million to $94 million • Non-GAAP EPS* of $0.12 to $0.20
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm
- Earnings Releases
  Bioventus Inc. reported Full Year 2023 results: revenue $512.3 million, net income net loss of $121.2 million, EPS ($1.54) loss per share.
  - Period: Full Year 2023
  - Revenue: $512.3 million
  - Net income: net loss of $121.2 million
  - EPS: ($1.54) loss per share
  - Result: reported results
  source text: Bioventus’ full-year 2023 worldwide revenue totaled $512.3 million, which was even compared to the prior year. On an organic* basis, revenue increased 3.6%, driven by 9.4% growth in Surgical Solutions. The Company also reported a full-year 2023 net loss from continuing operations of $121.2 million, compared to net loss from continuing operations of $144.7 million in the prior year. Adjusted EBITDA from continuing operations* of $88.9 million advanced 29.5% from $68.6 million last year due to disciplined cost management and savings from a corporate restructuring implemented at the beginning of the year. Loss per share of Class A common stock from continuing operations was $1.54 per share, compared to a loss of $1.70 per share last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.